Men’s Depression and Suicide

Oliffe, John L.; Rossnagel, Emma; Seidler, Zac E.; Kealy, David; Ogrodniczuk, John S.; Rice, Simon

doi:10.1007/s11920-019-1088-y

Cited by 99 publications

(97 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Respondents indicated how often (0="not at all", 1='several days', 2='more than half the days' and 3="nearly every day") they had experienced any of the listed symptoms over the previous 2 weeks (see Table 1 for items). Total scores reflect symptom severity: mild depression (total scores 5-9), moderate depression (total scores 10-14), moderately severe depression (total scores [15][16][17][18][19] and severe depression (total scores [20][21][22][23][24][25][26][27] with the scale demonstrating internal consistency in the present sample (α=0.89). Previous research has established the reliability and validity of the PHQ-9.…”

Section: Methodsmentioning

confidence: 91%

“…17 There is growing concern that these diagnostic criteria may inaccurately reflect men's experiences of mood disturbance, and therefore insufficiently identify men with an underlying mood disorder. 18,19 Studies support the existence of a phenotypic variant of depression in men, 20,21 characterised by externalising and atypical symptoms including anger, 22 substance use, 23 risk-taking 24 and emotion suppression. 25 These symptom domains tend to be socially sanctioned for men as reflecting culturally informed and affirmed dominant Western masculine norms (as opposed to vulnerable emotions of sadness).…”

mentioning

confidence: 99%

See 1 more Smart Citation

<p>The Cost of Bottling It Up: Emotion Suppression as a Mediator in the Relationship Between Anger and Depression Among Men with Prostate Cancer</p>

Rice

Kealy

Ogrodniczuk

et al. 2020

CMAR

Self Cite

View full text Add to dashboard Cite

Background: Prostate cancer is a risk factor for major depressive disorder. Recent psychooncology research suggests a potential role for male-specific mood-related symptoms in this relationship. Gender socialisation experiences may reinforce men's anger and emotion suppression responses in times of distress, and anger and emotion suppression may be implicated in pathways to, and maintenance of depression in prostate cancer. Patients and Methods: Data were collected online from men with a self-reported diagnosis of prostate cancer (N=100; mean age 64.8 years). Respondents provided information regarding diagnosis and treatment, in addition to current experience of major depression and male-specific externalising symptoms. Results: Prostate cancer diagnosis in the last 12 months occurred for 35.4% of the sample. Elevated major depression symptoms were observed for 49% of respondents, with 14% endorsing past 2-week suicide ideation. Parallel mediation analysis (99% CIs) controlling for prostatectomy and active surveillance indicated men's emotion suppression mediated the relationship between anger and depression symptoms (R 2 =0.580). Trichotimised emotion suppression scores with control variables yielded a large multivariate effect (p<0.001, partial η 2 =0.199). Univariate moderate-sized effects were observed for emotion suppression comparisons for symptoms of depressed mood and sleep disturbance, and a large effect observed for guilt-proneness. Conclusion: Findings highlight the salience of anger in the experience of depression symptoms for men with prostate cancer. The mediating role of emotion suppression, which in turn was strongly linked to men's feelings of guilt, suggests potential assessment and intervention targets. Future work should examine the role of androgen deprivation therapy and other treatments including active surveillance on the relationship between anger and depression in men with prostate cancer. Consideration of interventions focused on emotion processing skills in psycho-oncology settings may help reduce men's reliance on emotion suppression as a strategy for coping with feelings of anger or guilt in the context of prostate cancer.Men diagnosed with prostate cancer have a heightened risk for major depressive disorder, 1,2 with rates exceeding those seen in the general male population. 3,4 This finding has been linked to the unmet psychosocial needs of this population following diagnosis, 5 in addition to prostate cancer-related symptoms, 6 and treatmentinduced side effects including sexual dysfunction and urinary incontinence. 7-9 Even those men on active surveillance are at high risk for depression 10 whereby a decline Correspondence: Simon

show abstract

Section: Methodsmentioning

confidence: 91%

mentioning

confidence: 99%

<p>The Cost of Bottling It Up: Emotion Suppression as a Mediator in the Relationship Between Anger and Depression Among Men with Prostate Cancer</p>

Rice

Kealy

Ogrodniczuk

et al. 2020

CMAR

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, BDSA-J has the great advantage of being able to assess externalization problems related to mental health, including alcohol and substance abuse, and the presence or absence of suicidal ideation. In a population that tends to be predominantly male, such as elite athletes, not only internalization problems but externalization problems are often observed as symptoms of depression [ 28 , 29 ]. BDSA- J, which can assess both internalization and externalization issues, might be a useful tool for assessing depressive symptoms in elite athletes.…”

Section: Discussionmentioning

confidence: 99%

Developing a Japanese Version of the Baron Depression Screener for Athletes among Male Professional Rugby Players

Ojio

Matsunaga

Hatakeyama³

et al. 2020

IJERPH

View full text Add to dashboard Cite

The Baron Depression Screener for Athletes (BDSA) is a brief, valid, and reliable athlete- specific assessment tool developed in the US to assess depressive symptoms in elite athletes. We examined the applicability and reliability of a Japanese version of the BDSA (BDSA-J) in a Japanese context, and further examined the construct validity of the BDSA-J. Web-based anonymous self-report data of 235 currently competing Japanese professional male rugby players (25–29 years = 123 [52.3%]) was analyzed. A two-stage process was conducted to validate the factor structure of the BDSA-J using exploratory factor analysis in a randomly partitioned calibration sample, and confirmatory factor analysis in a separate validation sample. Cronbach’s alpha was used to assess internal consistency. Spearman’s rank-order correlation coefficients were calculated to examine convergent validity with the Kessler-6. We identified a one-factor structure for BDSA-J. Confirmatory factor analysis supported this one-factor model, revealing good model fit indices. The standardized path coefficients for each of the items were β = 0.52 to 0.79 (p < 0.001). A Cronbach’s alpha of 0.71 was obtained for the BDSA-J. BDSA-J showed significant positive correlations with the Kessler-6. The BDSA-J is an appropriate and psychometrically robust measure for identifying depressive symptoms in Japanese male rugby players.

show abstract

“…The MDRS progresses the early pioneering work of the Gotland research programme into men’s depression, established in Sweden in the 1990s. Whereas the male-type depression syndrome, as originally articulated by Rutz et al [ 17 ], has become a topic of significant interest in the men’s mental health literature [ 2 ], conclusive studies are yet to categorically support or refute the construct, with debate enduring [ 29 ].…”

Section: Introductionmentioning

confidence: 99%

Male-Type and Prototypal Depression Trajectories for Men Experiencing Mental Health Problems

Rice

Kealy

Seidler

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

Growing interest in gender-sensitive assessment of depression in men has seen the development of male-specific screening tools. These measures are yet to be subject to longitudinal latent modelling, which limits evidence about the ability of these tools to detect change, especially relative to established screening scales. In this study, three waves of data were collected from 234 men (38.35 years, SD = 14.09) including 3- and 6-month follow-up. Analyses focused on baseline differences and symptom trajectories for the Patient Health Questionnaire (PHQ; prototypic symptoms) and the Male Depression Risk Scale (MDRS; male-type symptoms). At baseline, men not accessing treatment reported higher MDRS scores relative to treatment-engaged men. There was no group difference for the PHQ. Internal consistency (α, ω) coefficients indicated comparable reliability for both measures across the three waves. Multidomain latent growth modelling, including current treatment engagement as a covariate, reported good model fit (CFI = 0.964, TLI = 0.986, RMSEA = 0.081, SRMR = 0.033) with differential findings for the PHQ and MDRS. Consistent with the baseline between-group analysis, current treatment effects were observed for the MDRS, but not the PHQ. Trajectory modelling for the MDRS indicated that greater severity resulted in slower improvement by 6 months. In contrast, there was no difference in the PHQ rate of change between baseline and 6 months. Findings support the psychometric utility of the MDRS as a male-specific symptom domain measure sensitive to both longitudinal change and potential treatment effects for symptomatic men, in ways not discernible by the PHQ. The MDRS may be a useful adjunctive screening tool for assessing men’s depression.

show abstract

Men’s Depression and Suicide

Cited by 99 publications

References 42 publications

<p>The Cost of Bottling It Up: Emotion Suppression as a Mediator in the Relationship Between Anger and Depression Among Men with Prostate Cancer</p>

<p>The Cost of Bottling It Up: Emotion Suppression as a Mediator in the Relationship Between Anger and Depression Among Men with Prostate Cancer</p>

Developing a Japanese Version of the Baron Depression Screener for Athletes among Male Professional Rugby Players

Male-Type and Prototypal Depression Trajectories for Men Experiencing Mental Health Problems

Contact Info

Product

Resources

About